This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Alpha Teknova, Inc.
11/4/2026
Hello, and welcome to Technova's third quarter 2026 financial results. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask the question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. I would now like to turn the call over to Jennifer Henry, Senior Vice President of Marketing. You may begin.
Thank you, Operator. Welcome to Technova's third quarter 2026 earnings conference call. With me on today's call are Stephen Gunstream, Technova's President and Chief Executive Officer, and Matt Lowell, Technova's Chief Financial Officer, who will make prepared remarks and then take your questions. As a reminder, the forward-looking statements that we make during this call, including those regarding business goals and expectations for the financial performance of the company, are subject to risks and uncertainties that may cause actual events or results to differ. Additional information concerning these risk factors is included in the press release the company issued earlier today, and they are more fully described in the company's various filings with the SEC. Today's comments reflect the company's current views. which could change as a result of new information, future events, or other factors, and the company does not obligate or commit itself to update its forward-looking statements except as required by law. The company's management believes that in addition to GAAP results, non-GAAP financial measures can provide meaningful insight when evaluating the company's financial performance and the effectiveness of its business strategies. We will therefore use non-GAAP financial measures of certain of our results during this call. Reconciliations of GAAP to non-GAAP financial measures are included in the press release that we issued this afternoon, which is posted to Technova's website and at www.sec.gov. Non-GAAP financial measures should always be considered only as a supplement to, and not as a substitute for, or as superior to, financial measures prepared in accordance with GAAP. The non-GAAP financial measures in this presentation may differ from similarly named non-GAAP financial measures used by other companies. Please also be advised that the company has posted a supplemental slide deck to accompany today's prepared remarks. It can be accessed on the investor relations section of Technova's website and on today's webcast. And now, I will turn the call over to Stephen.
Thank you, Jen. Good afternoon and thank you everyone for joining us for our third quarter 2026 earnings call. As you saw in the press release, we delivered our second consecutive quarter of record revenue with 22% top line growth compared to the same period last year. In addition to exceeding 20% growth for the first time in over four years, we are particularly encouraged that the growth came from sales of custom products to life science tools and diagnostics customers and, notably, to BioPharma customers. We believe the recent acceleration of revenue growth from sales to BioPharma customers is an early indication that we're benefiting from the increase in biotech funding that we've observed over the previous four quarters. Given this backdrop, we feel confident as we head into 2027. I'd like to start by providing more color about our revenue growth. As I mentioned, our above-market revenue growth is from sales of custom products. Catalog products, which were about 60% of revenue in 2025, have grown in the mid-single digits year-to-date. While sales to large pharma have grown in the mid-teens, total catalog growth was offset by headwinds from products sold into other biopharma end markets, like cell and gene therapy and contract manufacturing. We attribute that to the limited share of recent financing going toward early-stage programs and discovery work, but we expect that to change eventually if funding continues to increase. That said, this quarter we saw a significant uptick in custom product purchases from biopharma customers, much of which were for programs already in clinical trials. The growth was broad-based across multiple accounts and therapeutic modalities. Combined with our direct conversations with customers regarding planned purchases in 2027, the data lead us to believe that this revenue growth is tied to the recent increase in biotech funding, which multiple sources report is up approximately 70% on a trailing 12-month basis. We also saw continued robust revenue growth from sales of custom products to tools and diagnostics customers, like in the first half of 2026, with notable demand from liquid biopsy and sequencing-related applications such as spatial biology. Internally, the organization is performing well. Year-to-date, the number of custom-ordered line items increased by approximately 30%, and we've expanded our customer base by nearly 10%. Even with that growth, we've demonstrated our ability to scale without a significant increase in expenses. Apart from the planned $2 million annual increase in sales and marketing spend, operating expenses are flat year-to-date, and our gross margins expanded by about 400 basis points. We believe our costs will only increase modestly as the business continues to scale, which reflects the value of our previous investments in facilities, IT systems, and manufacturing infrastructure. We're also encouraged by the early traction of our two new launches, BuildTech our AI-powered custom configurator, and Filtek, our new dispensing system. Since we introduced the new version of Filtek in June, customers from more than 100 organizations have submitted more than 140 quote requests covering nearly 180 custom products. We're also seeing repeat use with more than 40% of October requests coming from returning customers. Just as important is the quality of that demand. Nearly every request is a unique formulation, and about a third are for RUO Plus or GMP-grade products, the higher quality tiers customers typically need as programs move toward clinical and commercial manufacturing. Therefore, we believe BuildTech is helping us capture custom demand earlier and positions us to grow with programs as they scale. On the manufacturing side, we introduced our Filtek dispensing system in September to meet the evolving needs of bioprocessing for emerging therapies. This unique system allows us to tailor our production of single-use bags to fit our customers' bioprocessing environments, including by combining a variety of bag sizes and aseptic connectors into a single lot and reducing the minimum order requirements, all with the same industry-leading turnaround times. Furthermore, by integrating more deeply into our customers' workflows, We believe they will be incentivized to remain a customer as they advance their therapies towards commercialization. This new capability is hitting the mark. We have already received many orders quoted through Filtek with more than 60% of them for GMP-grade products, reinforcing Filtek's fit for scale-up into clinical and commercial manufacturing. I also want to touch on M&A. We remain focused on Tuscan acquisition opportunities that would allow us to leverage our facilities, systems, and manufacturing infrastructures. Alongside those characteristics, we're also looking for opportunities through which we could expand into manufacturing additional reagents, such as proteins. Any attractive target would need to help us grow our addressable market and further differentiate our business while leveraging the commercial channel we have built. At the same time, We're confident in our organic strategy and are in a good position to be disciplined when considering valuations and integration risks. In closing, as we look toward the end of 2026, I'm proud of the progress we've made on our growth strategy. Our customer pipeline is strong, the investments we've made to scale are in place and working, and we are delivering operationally. I will now hand the call to Matt to walk through the financials.
You're reading a preview of the TKNO Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing